S. Res. 251 (Introduced in Senate) — Expressing the sense of the Senate that the United States Preventive Services Task Force should reevaluate its recommendations against prostate-specific antigen-based screening for prostate cancer for men in all age groups in consultation with appropriate specialists.

That it is the sense of the Senate that—

(1)

the United States Preventive Services Task Force should—

(A)

reevaluate its recommendation against prostate-specific antigen-based screening for prostate cancer for men in all age groups;

(B)

seriously engage and consult with specialists, including urologists and oncologists, as it reevaluates its recommendation; and

(C)

identify areas for additional research and evaluation of methods of treatment of, and screening procedures for, prostate cancer;

(2)

prostate cancer screening decisions should be made by each individual patient and his physician, taking into account the personal risk factors of the patient, such as his overall health, age, race, family history, and life expectancy, as well as his desire for eventual treatment if he is diagnosed with prostate cancer; and

(3)

steps should be taken to raise awareness of, and increase public knowledge about, prostate cancer, the benefits of early detection, and the appropriateness of screening tests.

Expressing the sense of the Senate that the United States Preventive Services Task Force should reevaluate its recommendations against prostate-specific antigen-based screening for prostate cancer for men in all age groups in consultation with appropriate specialists.

Cite this provision

Incoming references